CARMAT receivership proceedings: towards liquidation?

CARMAT, developer of the Aeson® artificial heart, has published an update regarding its receivership proceedings. The Versailles Economic Activities Court opened these proceedings on July 1, 2025. A takeover bid was submitted by HOUGOU, a company headed by Pierre Bastid, Chairman of the Board of Directors of CARMAT.

At the hearing on September 30, the Court ruled the offer inadmissible, as the conditions precedent had not been met, including the required financing. The receiver therefore requested conversion into compulsory liquidation, which will be examined on October 14, 2025.

This liquidation could result in total losses for shareholders and certain creditors. Trading in CARMAT shares remains suspended pending the outcome of the hearing.